Figures S1-S5 from Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin
Year: 2023
Type: other
Abstract: Figure S1 shows A. Concentration-dependent reduction of number of adherent LNCaP cells exposed to increasing concentrations of bufalin for 96 h; B. Representative photomicrograph of LNCaP cells exposed to bufalin at 2 concentrations for 48 h. Figure S2 shows A, Western blot detection of c-PARP, AR, PSA in LNCaP cells exposed to bufalin for 48 h. B, Western blot detection of c-PARP, AR, PSA in LNCaP cells exposed to bufalin for 24 h. Figure S3 shows gross appearance of paraffin embedded tumors (3rd-8th ranked for each group) selected for biomarker analyses. Figure S4 shows Western blot detection of HK2 (hexokinase-2), p-AKT and AKT in tumors from vehicle- or bufalin-treated mice. PC3 cell extract and LNCaP extract (LN) were used as positive control for HK2 and active AKT (p-AKT), respectively. Figure S5 shows a schematic integration of bufalin induced cellular effects to inhibit LNCaP prostate tumor growth.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362609990